stockrowMerck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −130.7%
- Free cash flow
- +77.0%
- Total debt
- +50.4%
Quarter to September 2026, against a year earlier
Follow MRK
Alert me
Merck & Co., Inc. (MRK) Return on assets
Merck & Co., Inc.'s return on assets over the twelve months to 30 September 2026 was 0.00%, down 14.4 percentage points from fiscal 2025 (14.4%). Over the past ten years it has ranged from 0.34% (fiscal 2023) to 15.3% (fiscal 2024); the current reading is higher than 91% of that period. That is below the Drug Manufacturers General industry median of 2.28% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 14.4% | (0.93) |
| FY2024 | 15.3% | 14.96 |
| FY2023 | 0.34% | (13.18) |
| FY2022 | 13.5% | 0.29 |
| FY2021 | 13.2% | 5.20 |
| FY2020 | 8.03% | (3.76) |
| FY2019 | 11.8% | 4.49 |
| FY2018 | 7.30% | 4.69 |
| FY2017 | 2.61% | (1.37) |
| FY2016 | 3.98% | (0.47) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 22.0% |
| AMGN Amgen Inc. compare | 10.1% |
| AZN AstraZeneca PLC compare | 9.41% |
| NVS Novartis AG compare | 8.94% |
| JNJ Johnson & Johnson compare | 8.25% |
| ABBV AbbVie Inc. compare | 7.32% |
| PFE Pfizer Inc. compare | 1.95% |
| MRK Merck & Co., Inc. | 0.00% |
| GILD Gilead Sciences, Inc. compare | −7.03% |
| Drug Manufacturers General industry median | 2.28% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on MRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement